Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA Diabetic rats

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3844-3851

  Chen, Ting ^a   Kagan, Leonid ^a   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Exenatide; Mathematical modeling; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; NICOTINAMIDE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXPOSURE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

EXENATIDE; MATHEMATICAL MODELING; PHARMACODYNAMICS; PHARMACOKINETICS; TYPE 2 DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; NIACINAMIDE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; VENOMS;

EID: 84883828905     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23682     Document Type: Article

References (33)

1. http://diabetes.niddk.nih.gov/dm/pubs/statistics/#dud.
2. Lebovitz HE. 1999. Type 2 diabetes: An overview. Clin Chem 45(8 Pt 2):1339-1345.
3. Drab SR. 2010. Incretin-based therapies for type 2 diabetes mellitus: Current status and future prospects. Pharmacotherapy 30(6):609-624.
4. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. 1992. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267(11):7402-7405.
5. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. 1993. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268(26):19650-19655.
6. Gallwitz B. 2006. Exenatide in type 2 diabetes: Treatment effects in clinical studies and animal study data. Int J Clin Pract 60(12):1654-1661.
7. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. 2001. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res 53(4):260-267.
8. Parkes DG, Pittner R, Jodka C, Smith P, Young A. 2001. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50(5):583-589.
9. Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, Watada H. 2009. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem Biophys Res Commun 390(3):809-814.
10. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L. 2008. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 372(9645):1240-1250.
11. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. 1998. Experimental NIDDM: Development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47(2):224-229.
12. Gao W, Jusko WJ. 2010. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther 336(3):881-890.
13. Chen T, Mager DE, Kagan L. 2013. Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res 30(3):751-760.
14. Mager DE, Jusko WJ. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507-532.
15. Balcombe JP, Barnard ND, Sandusky C. 2004. Laboratory routines cause animal stress. Contemp Top Lab Anim Sci 43(6):42-51.
16. Raman M, Radziuk J, Hetenyi G, Jr. 1990. Distribution and kinetics of glucose in rats analyzed by noncompartmental and compartmental analysis. Am J Physiol 259(2 Pt 1):E292-303.
17. Gopalakrishnan M, Suarez S, Hickey AJ, Gobburu JV. 2005. Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J Pharmacokinet Pharmacodyn 32(3-4):485-500.
18. Kolterman OG. 2003. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88(7):3082-3089.
19. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D. 2005. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study. Diabetes Technol Ther 7(3):467-477.
20. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L. 2011. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 96(5):1301-1310.
21. Kumar EKD, Janardhana GR. 2011. Antidiabetic activity of alcoholic stem extract of Nervilia plicata in streptozotocin-nicotinamide induced type 2 diabetic rats. J Ethnopharmacol 133(2):480-483.
22. Yamabe N, Kang KS, Zhu BT. 2010. Beneficial effect of 17β-estradiol on hyperglycemia and islet β-cell functions in a streptozotocin-induced diabetic rat model. Toxicol Appl Pharmacol 249(1):76-85.
23. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Shibasaki M. 2008. Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats. Basic Clin Pharmacol Toxicol 103(6):560-568.
24. Li XG, Li L, Zhou X, Chen Y, Ren YP, Zhou TY, Lu W. 2012. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. Acta Pharmacol Sin 33(11):1379-1386.
25. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. 1999. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48(5):1026-1034.
26. Landersdorfer CB, Jusko WJ. 2008. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet 47(7):417-448.
27. Mager DE. 2004. Exendin-4 pharmacodynamics: Insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 311(2):830-835.
28. Post TM, Freijer JI, DeJongh J, Danhof M. 2005. Disease system analysis: Basic disease progression models in degenerative disease. Pharm Res 22(7):1038-1049.
29. Cao Y, Gao W, Jusko WJ. 2012. Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats. Pharm Res 29(4):1078-1086.
30. Gao W, Bihorel S, DuBois DC, Almon RR, Jusko WJ. 2011. Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats. J Pharmacokinet Pharmacodyn 38(1):143-162.
31. Cao Y, Dubois DC, Sun H, Almon RR, Jusko WJ. 2011. Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats. J Pharmacol Exp Ther 339(3):896-904.
32. Jusko WJ, Landersdorfer CB. 2008. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet 47(7):417-448.
33. Frey N, Laveille C, Paraire M, Francillard M, Holford NH, Jochemsen R. 2003. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol 55(2):147-157.